In a potentially pivotal trial, PTC Therapeutics' experimental therapy for Huntington's disease (HD) met its primary endpoint, but questions about the data have raised doubts about the company's ...
James Taranto edits the Journal's op-ed pages. Until January 2017 he wrote the popular Best of the Web column for WSJ.com. In August 2007 he was named a member of the Journal's editorial board. From ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results